SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SangStat Med. (SANG) - 10 of 10 analysts say Strong Buy -- Ignore unavailable to you. Want to Upgrade?

To: Darth Vader who wrote (81)2/16/1998 5:54:00 PM
From: deadstrait  Read Replies (1) | Respond to of 184
 
Thymo is broadly use in Europe for treatment of rejection. The treatment
of GEHD induction therapy, most recent results of trial, shows Thymo with
a 4.2% rejection rate at one year. In one year data comparing Zenapax
with placebo there is no significant difference in the rate of rejection.

Conclusion:--The different products will gain market share and no one
product will garner the market.

Deadstrait


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News